What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday?
What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday?
The data presented at EHA include safety findings for all patients in the Phase 1a dose escalation study regardless of diagnosis (n=79) and efficacy findings for those patients with relapsed or refractory CLL (n=31).Sunday, Nurix Therapeutics Inc (NASDAQ:NRIX) announced the presentation of updated clinical data for NX-5948, an orally bioavailable degrader of Bruton's tyrosine kinase (BTK).
週日，Nurix Therapeutics Inc（納斯達克：NRIX）宣佈公佈針對NX-5948的更新臨床數據，該藥物是BRUTON'S酪氨酸激酶（BTK）的口服可降解藥物。
BTK inhibitors have become a major commercial class, with drugs such as BeiGene Inc's (NASDAQ:BGNE) Brukinsa (Zanubrutinib), Eli Lilly And Co's (NYSE:LLY) Jaypirca (Pirtobrutinib), Johnson & Johnson's (NYSE:JNJ) Imbruvica (Ibrutinib), and AstraZeneca Plc's (NASDAQ:AZN) Calquence (Acalabrutinib).
BTK抑制劑已成爲一種重要的商業類別，其中包括BeiGene Inc的Brukinsa（Zanubrutinib），Eli Lilly And Co的Jaypirca（Pirtobrutinib），Johnson & Johnson的Imbruvica（Ibrutinib）和AstraZeneca Plc的Calquence（Acalabrutinib）等藥品。
NX-5948 is being evaluated in an ongoing Phase 1a/b trial in adults with relapsed or refractory B-cell malignancies, including CLL and non-Hodgkin lymphoma (NHL).
NX-5948正在進行一項針對復發或難治性B細胞惡性腫瘤（包括CLL和非霍奇金淋巴瘤（NHL））的ongoing一期a/b試驗。
The data presented at EHA include safety findings for all patients in the Phase 1a dose escalation study regardless of diagnosis (n=79) and efficacy findings for those patients with relapsed or refractory CLL (n=31).
在EHA上展示的數據包括一期a劑量遞增研究中所有患者的安全性結果（無論診斷），其中包括（n=79）和CLL（n=31）的復發或難治性患者的療效發現。
Patients were treated with NX-5948 at doses ranging from 50 to 600 mg once daily by oral administration.
患者通過口服每日50至600毫克的NX-5948接受治療。
NX-5948 was well tolerated across all doses evaluated, with the most common treatment-emergent adverse events of purpura/contusion, thrombocytopenia, and neutropenia.
無論接受的劑量如何，NX-5948的耐受性均良好，併發生的最常見的治療相關性不良事件爲紫癜/淤血，血小板減少症和中性粒細胞減少症。
Among the efficacy-evaluable patients with CLL (n=26), NX-5948 treatment resulted in an objective response rate (ORR) of 69.2% across all doses tested.
在可評價療效的CLL患者（n=26）中，NX-5948治療在所測試的所有劑量中導致69.2%的客觀緩解率（ORR）。
Responses were observed as early as the first scan (8 weeks), and many patients experienced a deepening of their response with longer treatment time.
患者早期（8周）即出現療效，並且長時間的治療時間加深了許多患者的治療反應。
All responses remained ongoing as of the April 17 data cutoff.
所有療效反應截至4月17日的數據截止日期仍在繼續。
Dr. Linton also presented an updated case report detailing the response of one patient who entered the study with CLL with CNS involvement after undergoing three prior therapies.
林頓博士還宣佈了一份更新的病例報告，詳細說明了一名在接受三種前期療法後患有CNS受累的CLL患者的反應。
After daily treatment with 100 mg, and later 300 mg, of NX-5948, the patient exhibited a deepening response approaching complete response criteria by 36 weeks, with malignant cells eliminated in the cerebrospinal fluid (CSF) by 24 weeks.
在每日接受100毫克和300毫克NX-5948治療後，該患者在36周時出現了逼近完全緩解標準的深化反應，並在24周內消除了腦脊液（CSF）中的惡性細胞。
Another case report presented by the company involved a patient who had received eleven prior lines of therapy. After daily treatment with 200 mg of NX-5948, the patient achieved a response by week 8, which deepened over time and was ongoing with over six months of follow-up.
該公司報告的另一個病例報告涉及一名已接受11項前治療的患者。在每日接受200毫克NX-5948治療8周後，患者達到了療效，在隨訪超過6個月的時間內逐漸加深。
"We intend to move rapidly forward with the goal of initiating pivotal trial(s) with NX-5948 in 2025," said Arthur Sands, president and CEO of Nurix.
“我們打算迅速行動，目標是在2025年啓動NX-5948的關鍵試驗，”Nurix的總裁兼首席執行官Arthur Sands表示。
Analyst Reaction:
分析師反應：
- JP Morgan maintains Nurix with an Overweight rating, raising the price target from $30 to $31.
- Needham reiterates Nurix Therapeutics with a Buy and maintains $31 price target.
- 摩根大通（JP Morgan）維持Nurix的超額評級（Overweight），將價格目標從30美元上調至31美元。
- Needham重申了對Nurix Therapeutics的買入（Buy）意見，並維持31美元的價格目標。
Price Action: NRIX shares are down 3.26% at $14.69 at last check Monday.
NRIX股票在上週一的最後一次檢查時跌落3.26％至14.69美元。
Photo via Shutterstock
圖片來自shutterstock。
譯文內容由第三人軟體翻譯。